中国临床解剖学杂志 ›› 2025, Vol. 43 ›› Issue (1): 63-68.doi: 10.13418/j.issn.1001-165x.2025.1.10

• 实验研究 • 上一篇    下一篇

壮药扶正方通过改善Lewis肺癌CD8+ T细胞耗竭提高PD-L1抑制剂疗效的机制研究

莫娟梅1,    张顺荣1,    李健2,    王振宁1,    唐伟智1,    梁碧琦1,    庞宇舟2,    
周建龙1,    周韶璋3 ,    黄国东1*
  

  1. 1. 广西中医药大学附属国际壮医医院,  广西   南宁    530201;    2. 广西中医药大学,  广西   南宁   530200;    3. 广西医科大学附属肿瘤医院,  广西   南宁   530021
  • 收稿日期:2024-08-01 出版日期:2025-01-25 发布日期:2025-01-22
  • 通讯作者: 黄国东,博士,主任医师,E-mail: huangnong.2007@163.com
  • 作者简介:莫娟梅(1985-),女,在读博士,副主任医师, 研究方向:中西医结合诊疗研究,E-mail: mjm-201@163.com
  • 基金资助:
    广西中医药大学A类“桂派中医药传承创新团队”(2022A003);广西自然科学基金项目(2023GXNSFBA026074);国家自然科学基金项目(82360983)

The mechanism of Zhuang Medicine Fuzheng Compound improving the efficacy of PD-L1 inhibitor by improving CD8+T cell depletion in Lewis lung cancer

Mo Juanmei1, Zhang Shunrong1, Li Jian 2, Wang Zhenning1, Tang Weizhi2, Liang Biqi1, Pang Yuzhou2, Zhou Jianlong1, Zhou Shaozhang3, Huang Guodong1*   

  1. 1. Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530201, China; 2. Guangxi University of Chinese Medicine, Nanning 530200, China; 3. Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China
  • Received:2024-08-01 Online:2025-01-25 Published:2025-01-22

摘要: 目的    探讨壮药扶正方对小鼠肺癌浸润的CD8+ T细胞耗竭以及对PD-L1抑制剂疗效的影响,并明确其中可能的机制。  方法    MTT、平板克隆检测壮药扶正方对小鼠肺癌LLC细胞增殖能力影响;流式细胞术检测CD8+ T的比例以及检测PD-L1表达水平,并利用Western blot检测蛋白水平表达初步探讨相关机制;最后通过动物体内实验验证壮药扶正方和PD-L1抑制剂协同作用。  结果    壮药扶正方可抑制小鼠肺癌LLC细胞增殖能力;在小鼠体内实验中,壮药扶正方和PD-L1抑制剂可起到协同抗肿瘤作用;壮药扶正方延缓CD8+ T细胞的耗竭情况,并抑制PD-L1表达;壮药扶正方可降低PI3K/AKT通路活性。  结论    壮药扶正方可延缓CD8+ T细胞耗竭和抑制PD-L1表达,增强PD-L1抑制剂治疗肺癌的疗效,机制可能与降低PI3K/AKT信号通路有关。

关键词: 壮药扶正方; ,  , 肺癌; ,  , TIL细胞耗竭; ,  , PI3K/AKT信号通路; ,  , 增殖

Abstract: Objective    To investigate the effect of Zhuang Medicine Fuzheng Compound on the exhaustion of CD8+ T cells infiltrated by lung cancer and the efficacy of PD-L1 inhibitors, and to clarify the possible mechanism.    Methods    MTT and plate cloning were used to detect the effect of Zhuang Medicine Fuzheng Compound on the proliferation of LLC cells of mouse lung cancer. Flow cytometry was used to detect the proportion of CD8+T and the expression level of PD-L1, and Western blot was used to detect the expression level of protein to preliminarily explore the relevant mechanism. Finally, the synergistic effect of Zhuang Medicine Fuzheng Compound and PD-L1 inhibitor was verified by animal experiments.    Results Zhuang Medicine Fuzheng Compound inhibited the proliferation of LLC cells in mice. In vivo experiments in mice, Zhuang Medicine Fuzheng Compound and PD-L1 inhibitor could play a synergistic anti-tumor effect. Zhuang Medicine Fuzheng Compound delayed the depletion of CD8+ T cells and inhibited the expression of PD-L1. Zhuang Medicine Fuzheng Compound could reduce the activity of PI3K/AKT pathway.    Conclusions    Zhuang Medicine Fuzheng Compound can delay CD8+ T cell depletion and inhibit PD-L1 expression, and enhance the efficacy of PD-L1 inhibitors in the treatment of lung cancer, which may be related to the reduction of PI3K/AKT signaling pathway.

Key words: Zhuang Medicine Fuzheng Compound; ,  Lung cancer; ,  TIL cell depletion; ,  , PI3K/AKT signaling pathway; ,  , Proliferation

中图分类号: